NCCN Guidelines Reaffirm Support For Avastin In Metastatic Breast Cancer
Executive Summary
The influential NCCN Clinical Practice Guidelines for Oncology should retain its recommendation supporting use of Genentech/Roche’s Avastin (bevacizumab) in metastatic breast cancer, the National Comprehensive Cancer Network expert breast cancer panel voted 24-0, with 1 abstention, at its July 10-12 meeting. NCCN recommendations are often used by payers in establishing formulary and coverage policies.
You may also be interested in...
Payers Move Against Avastin: California Blue Shield Halting Coverage In Breast Cancer
Announcement follows similar moves by three smaller commercial payers earlier this year.